--- title: "Tencent Miying holds three medical Class III certificates — what China's AI radiology actually does in clinics" date: 2026-09-28 category: AI in Action site: NeuroAI canonical: https://neuroai.site/a/na-app-ai-medical-imaging language: en --- # Tencent Miying holds three medical Class III certificates — what China's AI radiology actually does in clinics > Tencent Miying (腾讯觅影), launched in 2017, is one of the few Chinese medical-AI products with multiple Class III device certificates — for glaucoma, colorectal polyp and pneumonia-CT screening. It shows how AI triage is being deployed in real hospitals, including rural clinics. In a county hospital in Jiangxi, one ophthalmologist reads dozens of fundus photos a day. An AI checks each in about four seconds and flags the ones a tired eye might miss. This is not a conference demo. The system cleared China's strictest medical-device bar and is installed in more than a hundred hospitals. For anyone watching AI in medicine, the useful question is not "can a model see a lesion?" It is "did it survive the regulator?" ## The product that entered the clinic **Tencent Miying (腾讯觅影)** launched in August 2017 as Tencent's first medical-imaging AI. Unlike many research projects, it pursued — and won — China's **Class III (三类) medical-device registrations**, the highest regulatory tier, where a product may be used as an auxiliary diagnostic system in hospitals. Three certificates anchor it: - **Chronic glaucoma-like optic neuropathy fundus image auxiliary diagnostic software** (注册证号 国械注准20223211140) — screens for glaucoma from fundus photos. - **Colorectal polyp electronic endoscope image auxiliary detection software** (国械注准20233210707) — flags polyps during colonoscopy; listed on 1 June 2023 and also recognised as an innovative device. - **Pneumonia CT image auxiliary triage and assessment software** (国械注准20213210612) — approved August 2021. Tencent says it holds **six medical-device registrations** across respiratory, eye and digestive diseases, making it one of the first internet companies with multi-disease, multi-modal medical AI certificates. ## What the certificates actually buy A Class III (三类) certificate is the difference between "interesting tool" and "something a hospital can procure." The clinical figures Tencent reports, drawn from product requirements and multi-centre trials, are specific: - **Glaucoma AI**: sensitivity 96%, specificity 92%; cuts missed-diagnosis rate by about 20% and misdiagnosis by about 2%; returns a result in roughly four seconds. - **Colorectal AI**: raises polyp detection by more than 20% and lowers missed-polyp rate by more than 20%. By early 2025 the glaucoma module alone had reached **over 100 medical institutions**, per Southern Metropolis Daily — a real, scaled deployment rather than a pilot. ## The COVID proving ground Miying's pneumonia AI earned its credibility under pressure. In February–April 2020, at Zhongnan Hospital of Wuhan University (武汉大学中南医院), the system helped read lung CTs for **more than 24,000 patients across two months**; at makeshift Leishenshan (雷神山) Hospital, reports landed within about 30 minutes of a scan. That emergency use became the basis for the 2021 Class III certificate. ## Where it helps most The clearest value is in **primary and rural care**, where specialists are thin. In Guangdong and Jiangxi, Miying powers regional eye-health screenings; one Jiangxi county hospital reported finding 13 glaucoma cases in a single month that a thinly staffed clinic might have missed. Deployment is hybrid: tier-3 hospitals run it locally for speed and data control, while grassroots sites use the cloud version to lower the barrier. ## What it cannot replace Miying is an **auxiliary (辅助) system** — a doctor still signs the diagnosis. Its reported accuracy figures are vendor numbers from trials, not independent head-to-head studies. And its coverage is limited to the diseases it was certified for; other modules remain research-use only. ## What readers can do now - **If you are a clinician in China**, treat a Class III (三类) certificate as the real procurement bar — model size matters less than regulatory clearance. - **If you build health AI**, the moat is the registration pathway and clinical evidence, not the architecture. - **If you follow policy**, watch how China's drug regulator (NMPA) reviews AI devices — the rules are still hardening. ## Honest limitations Core facts (Miying launch August 2017; the three Class III registration numbers and dates; six total registrations; glaucoma sensitivity/specificity and missed-diagnosis figures; colorectal detection uplift; 24,000+ patients in Feb–Apr 2020 at Zhongnan Hospital; 100+ institutions by early 2025) come from tencentmiying.com, cloud.tencent.com, GMW (光明网) and Southern Metropolis Daily / nfnews. Registration numbers are published by Tencent's official materials. All clinical performance figures are Tencent's vendor-reported numbers from product requirements and multi-centre trials and have not been independently audited. No RMB amounts are stated. Analysis is current to 28 September 2026. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-app-ai-medical-imaging Free to quote with attribution and a link to the original.